A Phase II Study of Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: Imatinib Dose Escalation
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 23
- 试验地点
- 1
- 主要终点
- progression-free survival (PFS)
研究概览
简要总结
KIT exon 9 mutants had poorer survival compared with KIT exon 11 mutants when they were treated with the same dose of imatinib, 400 mg per day, and that patients with KIT exon 9 mutation had better progression-free survival with imatinib treatment at an escalated dose, 800 mg per day, than with imatinib treatment at a dose of 400 mg per day.10,11 Based on the results, imatinib 800 mg per day is now considered the standard dose for the treatment of patients with metastatic or unresectable GIST showing KIT exon 9 mutation in Western countries.
详细描述
According to our previous prospective phase II study of imatinib 400 mg per day in metastatic or unresectable GIST, hematologic and non-hematologic toxicities were more frequent in Korean patients compared to the Western studies.7 It may be caused by relatively higher exposure to imatinib per body surface area in Korean patients than in Western population because the weight and height of Korean patients are relatively smaller than Western people. So, we plan to start imatinib at 400 mg per day and then sequentially escalate the doses of imatinib in this study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 or older
- •Histologically confirmed metastatic or unresectable GIST with CD117(+), DOG-1 (+), or KIT mutation
- •ECOG PS(Eastern Cooperative Oncology Group Performance Status) 0~2
- •Primary mutation at KIT exon 9
- •Imatinib treatment for less than 4 weeks from the first dose at 400 mg per day
- •No prior use of tyrosine kinase inhibitors ((but, patients who have recurrence 6 months after completion of adjuvant imatinib at a dose of 400 mg per day can be enrolled in this study)
- •At least one evaluable disease by RECIST v1.0
- •Resolution of all toxic effects of prior treatments (chemotherapy, surgery, RFA(radiofrequency ablation), radiotherapy, and/or TACE)
- •Adequate bone marrow function as defined by platelets ≥ 75 x 109/L and neutrophils ≥ 1.5 x 109/L (within 1 week prior to the first dose of imatinib at 400 mg per day)
- •Adequate renal function, with serum creatinine < 1.5 x ULN (within 1 week prior to the first dose of imatinib at 400 mg per day)
- •Adequate hepatic function with serum total bilirubin < 1.5 x ULN, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 2.5 x ULN in the absence of liver metastases, or < 5 x UNL in the presence of liver metastases (within 1 week prior to the first dose of imatinib at 400 mg per day)
- •No other malignant disease apart from non-melanotic skin cancer or carcinoma in situ of the uterine cervix or any other cancer except where treated with curative intent > 5 years previously without evidence of relapse
- •Provision of a signed written informed consent
排除标准
- •Severe co-morbid illness and/or active infections
- •Pregnant or lactating women
- •History of other malignancies except basal cell carcinoma and carcinoma in situ of uterine cervix
- •CNS metastasis
- •Clinically significant bleeding in GI tract
- •GI obstruction or malabsorption
- •Known hypersensitivity to imatinib
研究组 & 干预措施
Imatinib
干预措施: imatinib (Drug)
结局指标
主要结局
progression-free survival (PFS)
时间窗: up to 24months
evaluated with Triphasic or dynamic CT scans of abdomen \& pelvis, and other involved sites. Follow-up CT scans will be performed at 4 weeks and 12 weeks after the first dose of imatinib at 400 mg per day, and then every 3 months until disease using RECIST(Response Evaluation Criteria in Solid Tumors) version 1.0
次要结局
- disease control rate(Up to 24weeks)
- imatinib PK(pharmacokinetics) (Cmin)(up to 24months)
- safety control rate(up to 24months)
- overall survival (OS)(up to 24months)
- percentage of successful dose escalation(up to 24months)
研究者
Min-Hee Ryu
Professor
Asan Medical Center